stockrowCG Oncology, Inc.
CGON Healthcare Biotechnology
CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024.
- Revenue
- −3.72%
- EPS
- −12.3%
- Free cash flow
- −25.2%
- Total debt
- 0.00%
Quarter to September 2026, against a year earlier
Follow CGON
Alert me
CG Oncology, Inc. (CGON) Return on equity
CG Oncology, Inc.'s return on equity over the twelve months to 30 September 2026 was −28.3%, down 6.6 percentage points from fiscal 2025 (−21.7%). That is above the Biotechnology industry median of −50.1% and in line with the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −21.7% | 7.18 |
| FY2024 | −28.9% | (96.38) |
| FY2023 | 67.5% | 67.53 |
| FY2022 | 0.00% | — |
Return on equity against peers
| Company | Return on equity |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | 61.1% |
| LGND Ligand Pharmaceuticals Incorporated compare | 5.38% |
| MANE Veradermics Incorporated compare | 0.00% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 0.00% |
| CGON CG Oncology, Inc. | −26.4% |
| IMVT Immunovant, Inc. compare | −80.1% |
| SRRK Scholar Rock Holding Corporation compare | −167.8% |
| KOD Kodiak Sciences Inc. compare | −368.4% |
| MIRM Mirum Pharmaceuticals, Inc. compare | −760.0% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on CGON
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement